Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodayPrecious Metals
Gold Price TodayNew
Silver Price TodayNew
Platinum Price TodayNewSmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹4,277.9 Cr
Market Cap
Total market value of companyP/E Ratio
12.67
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
3.47
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹78.35
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
6.90%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
25.10%
ROCE
Return on Capital Employed. >15% is goodNet Margin
14.02%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
-%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
-%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
-6.86%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
87.10%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.31
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹441.46
Book Value
Net asset value per shareDividend Yield
0.66%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
68.80%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
4 points- •Epigral Ltd boasts a robust ROE of 22.60% and a high OPM of 27.80%, showcasing efficient operations and strong returns on investment. Its healthy ROCE of 25.10% further reinforces this financial strength.
- •The company demonstrates impressive quarterly profit growth, surging by 87.10%. This significant increase points to robust product demand and effective management strategies driving profitability.
Weaknesses
4 points- •Epigral Ltd's debt-to-equity ratio stands at 0.31, suggesting a moderate level of financial leverage. This could heighten financial risk, particularly during economic downturns or unexpected market shifts.
- •While quarterly profits show strong growth, quarterly sales have experienced a concerning -6.86% variance, signaling a potential slowdown in sales growth that warrants further investigation.
Opportunities
3 points- •Operating in the 'Specialty Chemicals' sector, Epigral is well-positioned to capitalize on the growing demand for specialized chemical products. This industry expansion offers significant long-term growth potential.
- •Increasing FII and DII holdings, from 1.38% to 3.06% and 0.22% to 4.78% respectively, signal growing institutional investor confidence. This influx of smart money can drive future stock price appreciation.
Threats
3 points- •Epigral operates in a competitive 'Specialty Chemicals' market with established players like Pidilite Inds. and Deepak Nitrite. Intense competition could pressure margins and market share, impacting profitability.
- •The stock's 52-week range from 1502.35 to 2242.55 indicates significant price volatility. This fluctuation exposes investors to potential capital erosion during market downturns or sector-specific corrections.
Segment-wise Financial Analysis
Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹1301.02 | +₹121.02 | +10.26% |
| R3 | ₹1249.87 | +₹69.87 | +5.92% |
| R2 | ₹1217.43 | +₹37.43 | +3.17% |
| R1 | ₹1198.72 | +₹18.72 | +1.59% |
| PIVOT | ₹1166.28 | -13.72 | -1.16% |
| CURRENT | ₹1180.00 | - | - |
| S1 | ₹1045.27 | -₹134.73 | -11.42% |
| S2 | ₹1096.42 | -₹83.58 | -7.08% |
| S3 | ₹1115.13 | -₹64.87 | -5.50% |
| S4 | ₹1147.57 | -₹32.43 | -2.75% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume+62.0% vs avg
1.49L
(13 Apr 2026)Delivery %-7.9% vs avg
42.6%
(13 Apr 2026)Avg Volume (20D)20-day average
0.92L
(12 Mar - 13 Apr)Avg Delivery %Trend ↑
50.5%
(12 Mar - 13 Apr)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Solar Industries India Ltd
1.20L ₹ Cr
Best Profit Growth
Rain Industries Ltd
178.00 %
Highest Dividend Yield
Gujarat Alkalies & Chemicals Ltd
3.27 %
Peer Comparison
| Company Name |
|---|
 Carborundum Universal Ltd |
 Finolex Industries Ltd |
 GHCL Ltd |
 Garware Hi Tech Films Ltd |
 Gujarat Alkalies & Chemicals Ltd |
 Gulf Oil Lubricants India Ltd |
 India Glycols Ltd |
 Kingfa Science & Technology (India) Ltd |
 PCBL Chemical Ltd |
 Polyplex Corporation Ltd |
 Rain Industries Ltd |
 Responsive Industries Ltd |
 Solar Industries India Ltd |
 Styrenix Performance Materials Ltd |
 Vishnu Chemicals Ltd |
About
Epigral Ltd
Epigral Limited is a prominent Indian manufacturer and seller of chlor-alkali and related chemical derivatives, operating both domestically and internationally. Their extensive product portfolio caters to a diverse range of industries, showcasing their broad reach and diverse applications within the chemical sector. The company's history, starting as Meghmani Finechem Limited before a name change in August 2023, highlights its growth and evolution in the market.
A core component of Epigral's business is the production and sale of chlorinated polyvinyl chloride (CPVC) resins and compounds. These materials find significant application in the manufacturing of CPVC pipes and fittings, demonstrating a key vertical integration within their operations. Beyond CPVC, Epigral also produces and supplies a wide array of other chemical products, including epichlorohydrin, various chloromethanes, hydrogen peroxide, caustic soda, potash, chlorine, and hydrogen. These products are further processed into other value-added chemicals like chlorotoluene, highlighting a commitment to comprehensive chemical manufacturing.
The breadth of industries served by Epigral underscores the versatility and demand for their chemical products. Their customer base spans sectors such as construction (using CPVC pipes), paints and coatings, electronics, water treatment, agrochemicals, pharmaceuticals, refineries, soap and detergent manufacturing, and various others, including the production of fluoropolymers, paper and pulp, textiles, alumina, polyurethane foam, lithium, and even PTFE pipes. This wide reach indicates Epigral’s strategic positioning across many crucial industrial sectors.
Epigral’s operations are not limited to chemical production; they also feature a significant energy component. The company operates a captive power plant (CPP) to support its manufacturing processes, ensuring a reliable and cost-effective energy supply. Furthermore, they have invested in renewable energy sources by operating a wind-solar hybrid power plant, demonstrating a commitment to sustainable practices and energy independence. This integrated approach to energy production underlines their commitment to operational efficiency and environmental responsibility.
COMPANY FACTS - EPIGRAL
Registered Address
Epigral Tower, B/h. Safal Profitaire, Corporate Road
Ahmedabad
GUJARAT
IN
Tel: 917929709600
Website:https://epigral.com/
Investor Relations:https://www.meghmanifinechem.com/investor-contact/
Company Details
Group: Materials
Sector: Materials
Industry: Chemicals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 1,072
IPO Date: 18/08/2021
MANAGEMENT - EPIGRAL
Mr. Maulik Patel
Chairman of the Board, Managing Director
Mr. Sanjay Jain
Chief Financial Officer
Mr. Gaurang Trivedi
Compliance Officer, Company Secretary
Mr. Kaushal Soparkar
Executive Director
Mr. Ankit Patel
Non-Executive Non-Independent Director
Mr. Darshan Patel
Non-Executive Non-Independent Director
Mr. Karana Patel
Non-Executive Non-Independent Director
Mr. Sanjay Asher
Non-Executive Independent Director
Ms. Priyanka Chopra
Non-Executive Independent Director
Mr. Kanubhai Patel
Non-Executive Independent Director
Shri. Manubhai Patel
Non-Executive Independent Director
Mr. Raju Swamy
Non-Executive Independent Director
Investor Questions Answered
Epigral Ltd (EPIGRAL) Stock FAQs
Get answers to the most common questions about Epigral Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Epigral Ltd (EPIGRAL) is ₹1,180. Today, the stock has gained by ₹51.70 (4.58%), trading in a range of ₹1,133.85 to ₹1,185. The stock opened at ₹1,133.85 with a trading volume of 1,16,826 shares.
Epigral Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹4,277.9 crores, P/E ratio of 12.67, ROE of 6.90%, and ROCE of 25.10%. The dividend yield stands at 0.66%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Epigral Ltd (EPIGRAL) is ₹2,114, while the 52-week low is ₹807. Currently trading at ₹1,180, the stock is 28.5% away from its 52-week low and 44.2% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Epigral Ltd stock at ₹1,180 depends on multiple factors. The stock is currently trading with a P/E ratio of 12.67 and P/B ratio of N/A. Today's performance shows a gain of 4.58%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Epigral Ltd offers a dividend yield of 0.66%, which means for every ₹100 invested at the current price of ₹1,180, you can expect to receive approximately ₹0.66 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Epigral Ltd's key financial metrics include: P/E Ratio: 12.67, P/B Ratio: N/A, ROE: 6.90%, ROCE: 25.10%, Dividend Yield: 0.66%, EPS: ₹78.35, Book Value: ₹441.46, Debt-to-Equity: 0.31, and Current Ratio: N/A. The company's market cap stands at ₹4,277.9 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Epigral Ltd stock opened at ₹1,133.85 and is currently trading at ₹1,180, showing a gain of ₹51.70 (4.58%). The intraday high is ₹1,185 and low is ₹1,133.85. The trading volume stands at 1,16,826 shares, indicating moderate market participation today.
Epigral Ltd has a Price-to-Earnings (P/E) ratio of 12.67, which means investors are willing to pay ₹12.67 for every ₹1 of earnings. With an EPS of ₹78.35, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
Epigral Ltd has a market capitalization of ₹4,277.9 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹1,180) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Epigral Ltd has a book value of ₹441.46 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹1,180, which is 167.3% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Epigral Ltd has a Return on Equity (ROE) of 6.90% and Return on Capital Employed (ROCE) of 25.10%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Epigral Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Epigral Ltd has a debt-to-equity ratio of 0.31, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Epigral Ltd has an Earnings Per Share (EPS) of ₹78.35, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹1,180 and P/E ratio of 12.67, investors are paying 12.67 times the annual earnings per share. This strong EPS indicates robust profitability. Track EPS growth over quarters to assess earnings momentum.
Epigral Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Epigral Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Epigral Ltd stock, consider: 1) Fundamental Analysis - Review P/E (12.67), ROE (6.90%), debt-to-equity (0.31), and growth rates. 2) Technical Analysis - Check 52-week range (₹807.00 - ₹2114.00), moving averages, and chart patterns. 3) Valuation - Compare current price (₹1180.00) with book value (₹441.46) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Epigral Ltd share is ₹10.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹1,180 is 11700x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Epigral Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹807.00 - ₹2114.00). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.31 indicates leverage. 4) Liquidity Risk - Based on trading volume of 1,16,826 shares. 5) Valuation Risk - P/E of 12.67 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Epigral Ltd operates in the industry with key metrics: P/E ratio of 12.67, ROE of 6.90%, market cap of ₹4,277.9 crores, and dividend yield of 0.66%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.31), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Epigral Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹1,180, with a 52-week range of ₹807.00 to ₹2114.00. Based on fundamentals like P/E (12.67), ROE (6.90%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Epigral Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹1180.00. 2) Fundamental Deterioration - Declining ROE (currently 6.90%), increasing debt (D/E: 0.31), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Epigral Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.66%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu